Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6454977 | 0.93 | TLR4 (0.38) | TLR4CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL6459078 | 0.93 | TLR4 (0.38) | TLR4CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL6454974 | 0.93 | TLR4 (0.38) | TLR4CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL6460414 | 0.91 | CYP2C9 (0.35) | TLR4CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL6454553 | 0.91 | CYP2C9 (0.35) | TLR4CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL6454556 | 0.91 | CYP2C9 (0.35) | TLR4CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL2884363 | 0.89 | CYP2C9 (0.43) | TLR4CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL8737129 | 0.89 | CYP2C9 (0.43) | TLR4CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL7569241 | 0.89 | CYP2C9 (0.43) | TLR4CYP2C9ALDH1A1LMNAMAPT | |
| SCHEMBL3437358 | 0.89 | CYP2C9 (0.43) | TLR4CYP2C9ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100264368-A1 | LIQUID CRYSTAL MOLECULES COMPRISING HYDROAZULENE STRUCTURES | TETRAGON-CHEMIE AG (LI) | 2010-10-21 | — | — | US | disclosed |
| EP-1896552-B1 | LIQUID CRYSTAL MOLECULES COMPRISING HYDROAZULENE STRUCTURES | TETRAGON CHEMIE AG (LI) | 2010-05-19 | — | — | EP | disclosed |
| EP-1896552-A1 | LIQUID CRYSTAL MOLECULES COMPRISING HYDROAZULENE STRUCTURES | Tetragon-Chemie AG (LI) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006136345-A1 | LIQUID CRYSTAL MOLECULES COMPRISING HYDROAZULENE STRUCTURES | TETRAGON-CHEMIE AG (LI) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100264368-A1 | LIQUID CRYSTAL MOLECULES COMPRISING HYDROAZULENE STRUCTURES | FLI1, F12, GTF2I | TLR4 4722/4885CYP2C9 3104/4885ALDH1A1 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.